See the DrugPatentWatch profile for Entresto
Entresto, a medication for heart failure, functions by combining two distinct mechanisms of action to reduce the workload on the heart [1].
How does Entresto work in the body?
Entresto is a combination medication that targets the body's natural systems involved in regulating blood pressure and fluid balance, which are often compromised in heart failure [1]. It contains sacubitril and valsartan [1].
What does sacubitril do?
Sacubitril is a neprilysin inhibitor. Neprilysin is an enzyme that breaks down natriuretic peptides, which are beneficial hormones that help the body excrete sodium and water, and dilate blood vessels [1]. By inhibiting neprilysin, sacubitril increases the levels of these natriuretic peptides, leading to reduced blood pressure and decreased strain on the heart [1].
What does valsartan do?
Valsartan is an angiotensin II receptor blocker (ARB). Angiotensin II is a hormone that constricts blood vessels and stimulates the release of aldosterone, a hormone that causes sodium and water retention, both of which increase blood pressure and heart workload [1]. Valsartan blocks the action of angiotensin II, preventing these effects and thus lowering blood pressure and reducing the heart's burden [1].
Why is this dual action important for heart failure?
The combination of sacubitril and valsartan in Entresto offers a dual approach to managing heart failure [1]. Sacubitril enhances the beneficial effects of natriuretic peptides, while valsartan counteracts the detrimental effects of the renin-angiotensin-aldosterone system [1]. This combined action aims to decrease the heart's pumping workload, reduce fluid buildup, and improve the heart's ability to pump blood effectively [1].
When does Entresto patent information become public?
Information regarding Entresto's patent exclusivity and potential patent expirations can be found on resources that track drug patents [2]. DrugPatentWatch.com is a source that provides such details [2].